National University Hospital, Singapore
nuh.com.sgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
438
Active
88
Phase 3
21
Total enrollment
141,880
Pipeline matrix
Showing 40 of 79 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Prednisolone | — | — | — | — | 3 | ||
| Methotrexate | — | — | — | — | 3 | ||
| Atorvastatin 40mg | — | — | — | — | — | 1 | |
| Omeprazole 20mg | — | — | — | — | — | 1 | |
| prilocaine | — | — | — | — | — | 1 | |
| Bupivacaine | — | — | — | — | — | 1 | |
| Folic Acid 5 MG | — | — | — | — | — | 1 | |
| Omeprazole 20 mg | — | — | — | — | — | 1 | |
| Doxycycline | — | — | — | — | 3 | ||
| Systemic Therapy/Standard of Care | — | — | — | — | — | 1 | |
| Menopausal hormone therapy | — | — | — | — | — | 1 | |
| Menopausal hormone therapy + exercise training | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | 3 | ||
| Cyclophosphamide | — | — | — | 4 | |||
| Lenvatinib + Letrozole | — | — | — | — | — | 2 | |
| Bevacizumab | — | — | — | — | 2 | ||
| Doxorubicin | — | — | — | 4 | |||
| Dexamethasone | — | — | — | 3 | |||
| Vincristine | — | — | — | — | 2 | ||
| L-Asparaginase | — | — | — | — | 2 | ||
| Imatinib | — | — | — | — | 2 | ||
| Cytarabine | — | — | — | — | 2 | ||
| Thioguanine | — | — | — | — | 2 | ||
| Fludarabine | — | — | — | — | 2 | ||
| Paclitaxel | — | — | — | — | 3 | ||
| ADG106 | — | — | — | — | — | 2 | |
| Pacritinib | — | — | — | — | — | 1 | |
| Extended Dosing Interval - A | — | — | — | — | — | 1 | |
| Extended Dosing Interval - B | — | — | — | — | — | 1 | |
| Extended Dosing Interval - C | — | — | — | — | — | 1 | |
| Standard of Care - A | — | — | — | — | — | 1 | |
| Standard of Care - B | — | — | — | — | — | 1 | |
| Standard of Care - C | — | — | — | — | — | 1 | |
| Dupilumab | — | — | — | — | — | 1 | |
| Co-intervention of Prednisolone wean during randomised controlled phase | — | — | — | — | — | 1 | |
| Dupilumab open label extension phase | — | — | — | — | — | 1 | |
| Co-intervention of Prednisolone wean during open label extension phase | — | — | — | — | — | 1 | |
| Pegylated asparaginase | — | — | — | — | — | 1 | |
| Erwinase | — | — | — | — | — | 1 | |
| Dasatinib | — | — | — | — | — | 1 |
39 more active programs hidden
Next readouts
- 2023-09-05
- 2024-07-31
- 2024-09-01
- 2025-08
- 2025-12
- 2025-12-01
- 2025-12-28
- 2026-03
- 2026-04
- 2026-05-01
Top conditions
- Breast Cancer33
- Gastric Cancer15
- Stroke12
- Cancer9
- Obesity8
- Non Small Cell Lung Cancer8
- Tuberculosis7
- Lung Cancer6
Frequently asked questions about National University Hospital, Singapore
- How many clinical trials does National University Hospital, Singapore have on ClinicalTrials.gov?
- National University Hospital, Singapore is listed as the lead sponsor on 438 clinical trials in ClinicalTrials.gov, 88 of which are currently active (recruiting, enrolling, or ongoing).
- How many of National University Hospital, Singapore's trials are in Phase 3?
- 21 of National University Hospital, Singapore's trials are in Phase 3, spread across 79 active drug programs.
- What therapeutic areas does National University Hospital, Singapore focus on?
- National University Hospital, Singapore's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Gastric Cancer, Stroke, Cancer, Obesity.
- When are National University Hospital, Singapore's next clinical trial readouts?
- National University Hospital, Singapore has 10 upcoming primary-completion readouts tracked here; the soonest is “Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients”, expected around 2023-09-05.